Revista espanola de medicina nuclear e imagen molecular最新文献

{"title":"Impact of left ventricular mechanical synchrony on systolic function assessed by gated myocardial perfusion imaging","authors":"Sümeyye Alkan,&nbsp;Alper Özgür Karaçalıoğlu","doi":"10.1016/j.remnie.2026.500283","DOIUrl":"10.1016/j.remnie.2026.500283","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to investigate the relationship between left ventricular phase analysis parameters and Peak Emptying Rate (PER) with ejection fraction (EF); to evaluate the role of PER in predicting early systolic dysfunction; and to examine how these parameters are affected by the severity of coronary artery disease (CAD) in patients with ischemia or infarction detected by gated myocardial perfusion scintigraphy (gMPS).</div></div><div><h3>Materials and methods</h3><div>Data from 430 patients who underwent myocardial perfusion scintigraphy for confirmed or suspected CAD were retrospectively analyzed. Based on perfusion defect scores, patients were categorized into three groups: normal (142 patients, SSS ≤ 3), ischemia (140 patients, SSS ≥ 4, reversible defect), and infarction (148 patients, SSS ≥ 4, fixed defect). Systolic and diastolic functional parameters of the left ventricle (EF, EDV, ESV, PER, PFR, TPFR) and synchrony indices (phase standard deviation [SD], histogram bandwidth [HBW]) were measured and compared across groups.</div></div><div><h3>Results</h3><div>EF values (65, 60, and 43%) and PER values (3.15, 2.94, and 2.06 s⁻¹) progressively decreased from the normal to the ischemia and infarction groups, with statistically significant differences among groups (p &lt; 0.001). Synchrony indices (SD and HBW) increased markedly, especially in the infarction group (mean HBW: 60.86–75.01 – 149.31; p &lt; 0.001). In both ischemia and infarction groups, significant correlations were observed between synchrony (HBW) and systolic (EF, PER) as well as diastolic (PFR, TPFR) parameters, with the strongest associations in the infarction group (p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Progressive coronary artery disease is associated with worsening left ventricular systolic and diastolic function, along with impaired mechanical contraction synchrony. PER may serve as a valuable scintigraphic parameter for improving the diagnostic assessment of left ventricular systolic function.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 5","pages":"Article 500283"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146260591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Spanish Society of Nuclear Medicine and Molecular Imaging’s position on preparing the health system for new Alzheimer’s disease treatments","authors":"Junta Directiva de la Sociedad Española de Medicina Nuclear e Imagen Molecular","doi":"10.1016/j.remnie.2026.500267","DOIUrl":"10.1016/j.remnie.2026.500267","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 5","pages":"Article 500267"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147313845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of [18F]F-choline PET/CT on the management of high-risk prostate cancer","authors":"C. Cases-Pellisé,&nbsp;J.L. Villa Palacios,&nbsp;R.M. Álvarez-Pérez,&nbsp;E.M. Triviño-Ibáñez,&nbsp;L. Brero Sánchez,&nbsp;V. Pachón Garrudo,&nbsp;I. Cejudo Liébana,&nbsp;R. Sánchez Sánchez,&nbsp;J.M. Jiménez-Hoyuela García,&nbsp;J.M. Freire-Macías,&nbsp;A. Rodríguez-Fernández","doi":"10.1016/j.remnie.2025.500272","DOIUrl":"10.1016/j.remnie.2025.500272","url":null,"abstract":"<div><h3>Objective</h3><div>To analyze the impact of [18F]F-Choline PET/CT findings on therapeutic management compared to conventional imaging techniques in the high-risk prostate cancer (PC) staging.</div></div><div><h3>Materials and methods</h3><div>Observational, longitudinal and retrospective study including patients with high-risk PC who underwent a [18F]F-choline PET/CT after initial staging with conventional imaging techniques (bone scan and abdomen-pelvis CT) between January 2018 and December 2023. Findings were classified as limited disease (lymph node involvement in pelvis and/or axial skeleton) or extended disease (extrapelvic lymph node involvement, involvement of extra-axial skeleton and/or distant sites). Finally, the impact of the results on therapeutic management and on disease volume reclassification (CHAARTED criteria) was analyzed.</div></div><div><h3>Results</h3><div>One hundred and nineteen patients were included (mean age: 68.43 ± 9.33 years, diagnostic prostate-specific antigen 64.22 ± 159.40 ng/mL). [18F]F-choline PET/CT was positive in 71.4% of patients (50.4% with limited disease and 21.0% with extended disease) versus 21.2% detected by conventional techniques (<em>P</em> &lt; .001). Based on PET findings, 18% of patients had high-volume disease compared to 5% based on conventional imaging (<em>P</em> = .002). [18F]F-choline PET/CT findings led to a change in therapeutic management in 54 patients (45.4%). Among them, 11 (9.2%) received radiotherapy to the pelvic lymph nodes, 14 patients (11.8%) hormone therapy, 23 patients (19.3%) were candidates for therapy with new antiandrogens, and 6 cases (5%) received systemic chemotherapy.</div></div><div><h3>Conclusion</h3><div>[18F]F-choline PET/CT is superior to conventional imaging techniques in high-risk prostate cancer staging, detecting 18% of patients with high-volume disease and leading to a change in therapeutic management in 45% of cases.</div></div><div><h3>Critical Relevance Statement</h3><div>[18F]F-choline PET/CT is superior to conventional imaging techniques in high-risk prostate cancer staging.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 5","pages":"Article 500272"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145902189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intrapulmonary Castleman disease mimicking locally advanced primary lung cancer on 18F-FDG PET/CT","authors":"D. Huang,&nbsp;X. Yang,&nbsp;Y. Chen,&nbsp;J. Gong","doi":"10.1016/j.remnie.2025.500213","DOIUrl":"10.1016/j.remnie.2025.500213","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 5","pages":"Article 500213"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145152570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of total gastrointestinal transit scintigraphy in the evaluation of patients with VEDOSS and systemic sclerosis.","authors":"L Casas Calabuig, J R Infante de la Torre, C Valera Ribera, F Montenegro Muñoz, J J Alegre Sancho, F Cavagna Matti, G Bonino, P Abreu Sánchez, J Orozco Cortés, M Á Navas de la Cruz, D Balaguer Muñoz, E Caballero Calabuig","doi":"10.1016/j.remnie.2026.500355","DOIUrl":"10.1016/j.remnie.2026.500355","url":null,"abstract":"<p><strong>Objective: </strong>The gastrointestinal tract is one of the systems most frequently involved in systemic sclerosis (SSc). The objective was to analyze gastrointestinal functional involvement by means of total gastrointestinal transit scintigraphy in patients with established SSc and in the early stages (VEDOSS), comparing both groups and evaluating the relationship between scintigraphic findings and general clinical and pulmonary functional variables.</p><p><strong>Materials and methods: </strong>Prospective study with 30 patients (21 with VEDOSS and 9 with SSc). Clinical, laboratory, imaging and pulmonary function parameters were evaluated. The scintigraphic study included esophageal transit, gastric emptying of solids and liquids, small bowel transit and colonic transit up to 72 h. Progression was analyzed by means of quantitative regional transit parameters, including the colonic geometric center.</p><p><strong>Results: </strong>The study was abnormal in 85.7% of patients with VEDOSS and in 88.8% of patients with SSc. The most frequent abnormalities were observed in the esophagus (60% of cases), colon (56.7%) and solid gastric emptying (30%). No statistically significant differences were observed between the two groups under study. A total of 46.7% of patients presented altered patterns in several segments. A significant correlation was found between disease duration and quantitative esophageal transit values, with no association between scintigraphic findings and pulmonary function tests.</p><p><strong>Conclusions: </strong>Gastrointestinal involvement in SSc was highly prevalent, heterogeneous and detectable from the early stages of the process. Total gastrointestinal transit scintigraphy provided a global and regional evaluation, facilitating the early diagnosis of dysmotility and optimizing personalized patient follow-up.</p>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500355"},"PeriodicalIF":0.0,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148868382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sacral neurolymphomatosis: Resolving a clinical enigma with ¹⁸F-FDG PET/MRI.","authors":"C González Roiz, L F León Ramírez, P Recarte Ortega, A Duque Taurá, L García Cañamaque","doi":"10.1016/j.remnie.2026.500345","DOIUrl":"10.1016/j.remnie.2026.500345","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500345"},"PeriodicalIF":0.0,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148868436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁸F-FDG PET/CT metabolic parameters-derived prediction model for microsatellite instability in colorectal cancer.","authors":"R Chen, L Deng, J Wang, C Lin, Q Gong","doi":"10.1016/j.remnie.2026.500344","DOIUrl":"10.1016/j.remnie.2026.500344","url":null,"abstract":"<p><strong>Objective: </strong>To create a non-invasive model for forecasting microsatellite instability (MSI) status in colorectal cancer (CRC) using preoperative ¹⁸F-FDG PET/CT metabolic parameters, guiding personalized treatment.</p><p><strong>Methods: </strong>A total of 156 pathologically confirmed CRC patients who underwent ¹⁸F-FDG PET/CT at Mindong Hospital affiliated to Fujian Medical University (November 2023 - August 2025) were retrospectively enrolled. Twenty-one parameters (demographic, clinical, pathological, PET/CT metabolic and heterogeneity indices) were collected. MSI status was determined by immunohistochemistry (IHC) for four mismatch repair (MMR) proteins (MLH1, MSH2, MSH6, PMS2). After variable selection by LASSO regression and collinearity elimination through correlation analysis, a nomogram model was constructed using multivariate logistic regression. Model performance was evaluated by ROC, calibration, and decision curves, with internal validation using LOOCV, 5-fold cross-validation, and bootstrapping.</p><p><strong>Results: </strong>Among patients, 28 (17.95%) were microsatellite instability-high (MSI-H, deficient mismatch repair, dMMR) and 128 (82.05%) were microsatellite stable (MSS, proficient mismatch repair, pMMR). Independent predictors included mucinous component, lymph node metastasis, differentiation grade, tumor size, and metabolic tumor volume (MTV). The model's AUC was 0.883 (95% CI: 0.820-0.945), with a sensitivity of 0.789 and a specificity of 0.857. Calibration curves and the Hosmer-Lemeshow test (χ² = 8.641, P = 0.3734) indicated good calibration of the model, and decision curve analysis showed that the model provided high net benefit. The AUCs of internal validation ranged from 0.801 to 0.857, which confirmed the good stability of the model.</p><p><strong>Conclusion: </strong>The integrated model established in this study is expected to assist in the non-invasive evaluation of MSI in CRC and may provide certain reference value for individualized clinical decision-making.</p>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500344"},"PeriodicalIF":0.0,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148868730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical consensus document on the use of [¹⁷⁷Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.","authors":"N Álvarez Mena, A Gómez-Grande, Z Nogareda Seoane, S Prado Wohlwend, A Rodríguez Fernández, M Rodríguez Fraile, J L Vercher Conejero, M Mitjavila Casanovas","doi":"10.1016/j.remnie.2026.500336","DOIUrl":"10.1016/j.remnie.2026.500336","url":null,"abstract":"<p><p>El cáncer de próstata resistente a la castración metastásico (CPRCm) representa un importante desafío clínico en oncología, tanto por su complejidad biológica como por su impacto en la calidad de vida y la supervivencia de los pacientes. La incorporación de [¹⁷⁷Lu]Lu-PSMA-617 en la práctica clínica plantea oportunidades relevantes, pero exige una adecuada coordinación multidisciplinar, protocolos claros de selección de los pacientes y un manejo cuidadoso de los aspectos logísticos y de seguridad radiológica. La variabilidad en la disponibilidad de recursos y en la experiencia entre centros hace especialmente valiosa la elaboración de unas guías prácticas adaptadas a la realidad asistencial. A diferencia de las guías internacionales, centradas principalmente en aspectos técnicos y regulatorios, este documento pretende ofrecer recomendaciones prácticas adaptadas a la realidad asistencial del Sistema Nacional de Salud español para la implantación de la terapia con [¹⁷⁷Lu]Lu-PSMA-617 en pacientes con CPRCm. Ha sido elaborado por un panel de especialistas en medicina nuclear con experiencia en terapias con radioligandos, a partir de una revisión no sistemática de la literatura (ensayos de registro, guías de procedimiento internacionales EANM y SNMMI, criterios PROMISE V2y PCWG4, y documentación regulatoria aplicable), de la práctica clínica de los autores y de un proceso iterativo de discusión y consenso del panel mediante reuniones de trabajo. La guía aborda los criterios de indicación y selección de los pacientes (incluyendo las restricciones de financiación del Sistema Nacional de Salud), el procedimiento terapéutico estandarizado, el seguimiento clínico, el manejo de las toxicidades, las cuestiones prácticas del día a día y las áreas de incertidumbre. Su objetivo es facilitar la toma de decisiones clínicas y contribuir a la armonización de protocolos entre centros.</p>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500336"},"PeriodicalIF":0.0,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148868668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative detection performance of PET and conventional scintigraphy tracers for inflammation and infection in bone and soft tissue: A systematic review and network meta-analysis.","authors":"H N Wang, C K Huang, Y E Huang, Y T Huang, S H Chan, J R Tseng","doi":"10.1016/j.remnie.2026.500341","DOIUrl":"10.1016/j.remnie.2026.500341","url":null,"abstract":"<p><strong>Introduction and objective: </strong>The optimal radiotracer for detecting infection and inflammation remains uncertain due to limited direct comparative data. This systematic review and network meta-analysis (NMA) aimed to evaluate and rank the diagnostic performance of various positron emission tomography (PET) and conventional nuclear medicine tracers in bone and soft tissue.</p><p><strong>Methods: </strong>PubMed, Embase, Cochrane Library, and ClinicalTrials.gov were systematically searched through February 2026 for studies comparing at least two radiotracers for infection or inflammation detection. The outcome was the DR. Pooled relative risks (RRs) and 95% confidence intervals (CIs) were estimated using a frequentist random-effects NMA with ⁶⁷Ga-citrate as the reference node.</p><p><strong>Results: </strong>Thirteen studies involving 558 subjects and lesions were included, forming a network of 10 radiotracers (three PET and seven conventional scintigraphy probes). Relative to ⁶⁷Ga-citrate, ⁶⁸Ga-FAPI had the highest estimated DR (RR 1.94; 95% CI, 0.88-4.30), followed by ¹⁸F-FDG (RR 1.63; 95% CI, 0.81-3.26), however, neither difference reached statistical significance. Among conventional agents, ^99mTc-DMSA(V) and ^99mTc-HMPAO-WBC ranked highest, whereas ^99mTc-nanocolloid yielded a lower DR than the reference (RR 0.69; 95% CI, 0.48-0.99). ^99mTc-MDP had the lowest DR in the network (RR 0.64; 95% CI, 0.38-1.07). The third PET tracer, ⁶⁸Ga-citrate, ranked seventh - below several conventional scintigraphy agents.</p><p><strong>Conclusion: </strong>Our findings suggest that ⁶⁸Ga-FAPI and ¹⁸F-FDG may offer the highest estimated DRs for bone and soft tissue infection and inflammation, while ^99mTc-HMPAO-WBC appears to perform best among scintigraphy probes. The observation that ⁶⁸Ga-citrate ranked below several conventional tracers suggests that detection performance may depend not only on the imaging platform but also on the biological targeting mechanism of the radiopharmaceutical. Given the limited number of studies, these rankings should be interpreted with caution and warrant further validation in large-scale comparative trials.</p>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500341"},"PeriodicalIF":0.0,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148868673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Duration of levothyroxine discontinuation and pre-radioiodine TSH levels in thyroid cancer.","authors":"G Mintegui, Z Martínez, M Basantes, R Ferrando","doi":"10.1016/j.remnie.2026.500335","DOIUrl":"10.1016/j.remnie.2026.500335","url":null,"abstract":"<p><strong>Introduction: </strong>Radioiodine treatment in differentiated thyroid carcinoma requires elevated TSH levels to optimize the uptake of [131I]NaI. Levothyroxine suspension is the usual strategy for inducing endogenous TSH elevation, although the optimal duration of this suspension remains controversial.</p><p><strong>Objective: </strong>To evaluate the effect of the duration of levothyroxine suspension on TSH levels achieved prior to radioiodine treatment.</p><p><strong>Materials and methods: </strong>Retrospective cohort study that included 104 patients with differentiated thyroid carcinoma treated at a reference university center. Patients were classified according to the time of discontinuation of levothyroxine prior to radioiodine treatment: three weeks (group A, n = 21) and four weeks (group B, n = 83). TSH levels between groups and their distribution by categories (<30, 30-49, 50-69, 70-99 y ≥100 mIU/L) were analyzed. The proportion of patients who reached the recommended TSH threshold (≥30 mIU/L) was also evaluated.</p><p><strong>Results: </strong>The mean age (SD) was 46.7 (10.3) years and 87 patients were women. The mean TSH was 70.9 mIU/L (95% CI: 54.5-87.2) in group A and 88.7 mIU/L (95% CI: 84.8-92.6) in group B. The proportion of patients who achieved TSH ≥ 30 mIU/L was significantly higher in group B (100% vs 76.2%; p < 0.001). The distribution of TSH levels by category differed significantly between both groups (p < 0.001). On the other hand, the proportion of patients with TSH ≥ 100 mIU/L did not show significant differences (60.2% vs 47.6%; p = 0.42). In multivariate analysis adjusted for age, sex, and radioiodine dose, levothyroxine discontinuation time was not independently associated with the likelihood of TSH ≥ 100 mIU/L.</p><p><strong>Conclusions: </strong>Three weeks of levothyroxine suspension allowed TSH levels ≥30 mIU/L to be reached in most patients, although a proportion did not reach the recommended threshold. Four weeks were associated with adequate TSH elevation in all patients in this cohort. TSH monitoring during preparation could allow for more individualized strategies that optimize thyroid stimulation, minimizing unnecessary exposure to hypothyroidism.</p>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500335"},"PeriodicalIF":0.0,"publicationDate":"2026-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148860684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}